Tenofovir-related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine
| Title: | Tenofovir-related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-Didanosine |
|---|---|
| Authors: | Rollot, MD, Florence; Nazal, Eve-Marie; Chauvelot-Moachon, Laurence; Kelaidi, MD, Charikleia; Daniel, Nathalie; Saba, Mona; Abad, Sebastien; Blanche, Philippe |
| Publisher: | Clinical Infectious Diseases |
| Date Published: | December 15, 2003 |
| Reference Number: | 640 |
Tenofovir-related tubular damage, like all other recently reported cases, occurred in patients receiving the protease inhibitor (PI) ritonavir, often with lopinavir. Increased plasma concentrations of didanosine were also observed after the addition of tenofovir. It was suspected that tenofovir with PIs interacted with renal organic anion transporters, leading to nephrotoxic tubular concentrations of tenofovir and systemic accumulation of didanosine. Until there is a better understanding of these interactions, close monitoring is recommended for patients receiving tenofovir, PIs, and didanosine.
|
You may, however, read this article at the Clinical Infectious Diseases website. To return to this page, use your "back" key. |